Valdecoxib (SC 65872) is a potent and selective inhibitor of COX-2 with IC50 of 5 nM, shows no activity against COX-1. Valdecoxib inhibits LPS-induced proliferation of endothelial cells and bFGF secretion in a dose-dependent manner. Valdecoxib stimulates VEGF formation via HMEC-1 under inflammatory conditions. shows chronic antiinflammatory activity in the rat adjuvant arthritis model, with an ED50 of 0.032 mg/kg/day). Valdecoxib (10 mg/kg, i.p.) significantly attenuates the behavioral and biochemical (oxidative damage) alterations in chronic-stressed mice. Valdecoxib also selectively blocks rat TRPV2 channels in HEK293 and RBL-2H3 cells with IC50 of 9 and 11 uM, respectively, but not closely related TRPV1, TRPV3 or TRPV4 channels.
